General discussion, page-20221

okay. You’re technically correct in that it hasn’t been approved...yet. But the likelihood of it being approved by the FDA is very high by the end of this year, which is a major factor why IHL is written off by US investors.

Lilli showed a mean reduction of up to 63% on the AHI scale and 51% of patients met the criteria for disease resolution. With big pharma in the back pocket of the FDA, there’s no way the drug won’t be approved before end of year to treat OSA. They have already got fast track approval from the FDA as well.

I can’t see why the coming phase 2b event won’t be another pump and dump. There soon won’t be an unmet need for OSA. Theres also absolutely no interest by US investors for this reason imo and share holder sentiment - the most important thing for the share prices- is dead and buried.

I love your confidence but the most shareholders (ex-management) can hope for is breakeven given the fundamentals have changed imo.